SS
ADCT icon

SBI Securities’s ADC Therapeutics ADCT Stock Holding History

SBI Securities’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$238 Buy
+222
New +$648 ﹤0.01% 3274
2026
Q1 		– Sell
-222
Closed -$784 – 4014
2025
Q4 		$784 Sell
222
-4
-2% -$16 ﹤0.01% 2726
2025
Q3 		$904 Buy
226
+4
+2% +$13 ﹤0.01% 2736
2025
Q2 		$595 Hold
222
– – ﹤0.01% 2900
2025
Q1 		$313 Sell
222
-10
-4% -$17 ﹤0.01% 3049
2024
Q4 		$462 Buy
+232
New +$607 ﹤0.01% 2918

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

SBI Securities's ADCT Position: Q2 2026 in Review

SBI Securities opened a new position in ADC Therapeutics (ADCT) in Q2 2026: 222 shares worth $238. The stake represents ﹤0.01% of the portfolio and ranks #3274 among its holdings. This is a return to the name: SBI Securities previously reported a position in ADCT as recently as Q4 2025.

SBI Securities first reported a position in ADCT in Q4 2024 and has held it in 6 quarters since. The position peaked at $904 in Q3 2025. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • SBI Securities held 222 shares of ADC Therapeutics worth $238 as of Q2 2026.
  • ADC Therapeutics was a new SBI Securities position in Q2 2026.
  • ADC Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3274 holding.
  • SBI Securities first reported a position in ADC Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • SBI Securities's ADC Therapeutics position peaked at $904 in Q3 2025.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.